| Similar Articles |
|---|
 |
The Motley Fool
October 18, 2007
Brian Lawler |
MGI's Quiet Gains The specialty pharma notches a healthy third-quarter and should keep performing well into the future. Investors, take note.   |
The Motley Fool
December 11, 2007
Brian Lawler |
The MGI Deal Makes Sense MGI Pharma announces it is being acquired by Japanese pharma giant Eisai for $3.9 billion. |
The Motley Fool
September 3, 2004
Charly Travers |
MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions. |
The Motley Fool
October 23, 2006
Brian Lawler |
MGI's Anonymous Growth If there's a value stock in the pharma world, this may be it. |
BusinessWeek
August 9, 2004
Gene G. Marcial |
MGI Pharma Has Just What Patients Need Its first major drug, an injection to prevent chemotherapy-induced nausea and vomiting, is on fire in a $1.5 billion market. And turning MGI into a moneymaker. |
The Motley Fool
November 30, 2007
Brian Lawler |
MGI's Turn for "Strategic Alternatives" MGI Pharma is the latest in a growing list of drugmakers looking for someone to acquire them. The company may be a relatively more attractive takeover target than other drugmakers, because it's two lead drugs are unpartnered in the U.S. |
The Motley Fool
October 16, 2006
Brian Lawler |
MGI Drug Approval Falters The FDA gives the thumbs-down to Saforis. However, investors should take notice of this well-run pharmaceutical. |
The Motley Fool
November 27, 2006
Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. |
The Motley Fool
December 28, 2006
Brian Lawler |
Pliva's Late Christmas Gift to Barr Normally generic drug competitors, Barr Pharmaceuticals and Par Pharmaceutical Companies announced the launch of a generic version of GlaxoSmithKline's drug, Zofran. Investors, take note. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
BusinessWeek
March 12, 2007
Gene G. Marcial |
SuperGen Is Looking Healthier Biotechs are gaining traction this year as fund managers discover many with viable products that are still underpriced. |
BusinessWeek
September 4, 2006
Gene G. Marcial |
A Super Outlook For SuperGen Biotechs have not fared well in this fickle market. |
The Motley Fool
January 31, 2007
Brian Lawler |
Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
The Motley Fool
December 4, 2007
Brian Lawler |
Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash. |
The Motley Fool
July 3, 2008
Brian Lawler |
Celgene Savors the Schadenfreude Bad news for a rival is a bonanza for drugmaker Celgene. |
The Motley Fool
April 25, 2006
Brian Gorman |
Pharma Plays With Fire Drugmakers' short-term gain could lead to long-term pain. |
The Motley Fool
January 30, 2007
Brian Lawler |
Par Passes the Generic Bar Par Pharmaceutical Companies gets approval to market another generic product, but the company still has to complete the restatement of its past financials. Investors, take note. |
Pharmaceutical Executive
January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
The Motley Fool
December 7, 2007
Brian Lawler |
Drugmakers Gear Up for ASH Cancer-focused drugmakers will be presenting their most promising data at two premiere medical conferences. Investors, take note. |
Pharmaceutical Executive
November 1, 2006
Marcee Nelson |
Direct to Consumer: Emotional Connection By reaching out to women, pharma companies can build more meaningful brands. |
Managed Care
September 2006 |
Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association. |
